newsfilter
← Latest News
ClinicalTrials.gov·

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC - NCT04846478

Rate of Dose Limiting Toxicity (DLT), Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0, Overall response rate (ORR)